Clinical trials: Bladder Tumors
Breast Cancer, Bladder Cancer
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid…
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer
- Trial name
- NCT00579514
- Testing
- PCR/PCR/LDR Strategy
- Where
- United States
- Volunteers
- 21,081 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer (Adenocarcinoma), Bladder Cancer
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
This trial tests if AI can help make medical info clear and readable. Many patients struggle to find medical informations that easy to read and understand from verified medical sources.
- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Trial name
- NCT07568444
- Testing
- Pub2Post
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Bladder Cancer, Liquid Biopsy
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
High-risk non-muscle-invasive bladder cancer (NMIBC) carries a substantial risk of residual disease after initial transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT07130578
- Testing
- urine tumor DNA/RNA testing
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Stage II Breast Cancer, Stage III Breast Cancer
Ask Questions (ASQ):Implementation of a Communication Intervention
This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting.
- Conditions
- Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer
- Trial name
- NCT05025748
- Testing
- Behavioral Intervention
- Where
- 8 sites in United States
- Volunteers
- 81 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-muscle-invasive Bladder Cancer
External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
Independent validation of Uromonitor as a non-invasive biomarker of recurrence of Non Muscle Invasive Bladder Cancer
- Trial name
- EVALUATION (NCT05864599)
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- Pharmalink
Muscle Invasive Bladder Carcinoma
A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in perioperative treatment of muscle-invasive bladder cancer.
- Trial name
- NCT05297552
- Testing
- RC48-ADC, JS001
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Bladder cancer that has not invaded the bladder muscle often returns after treatment, creating repeated procedures and ongoing anxiety for patients.
- Trial name
- NCT07347132
- Testing
- En Bloc Transurethral Resection of Bladder Tumor, Conventional Transurethral Resection of Bladder Tumor
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital
Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
- Trial name
- NCT00645593
- Testing
- Gemcitabine,, Cisplatin, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, CLE
Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment
A prospective monocenter diagnostic accuracy study of Confocal Laser Endomicroscopy (CLE) for Bladder Cancer(BC) to assess two primary objectives: 1.
- Trial name
- CLETUR (NCT05273593)
- Testing
- Confocal Laser Endomicroscopy (CLE)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
This study is an open, single-arm, single-center exploratory clinical study to explore the efficacy and safety of Disitamab Vedotin (RC-48) in combination with radiotherapy for the treatment of patients with HER2-expressing…
- Trial name
- NCT07100184
- Testing
- Disitamab Vedotin combined with Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Healthy Volunteers
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.
- Trial name
- NCT06435039
- Testing
- APL-1202, APL-1501
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Bladder Cancer, Metastatic Transitional Cell Carcinoma
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
The purpose of this study is to learn what effects, good and/or bad, Everolimus has on advanced urothelial cancer. The goal of this clinical research study is to learn if the study drug Everolimus can shrink or slow the growth of…
- Trial name
- NCT00805129
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
The goal of this clinical trial is to learn if neoadjuvant intravesical instillation of mitomycin C combined with en-bloc surgery works to treat high-risk non-muscle-invasive bladder cancer (NMIBC) patients.
- Trial name
- NCT06696794
- Testing
- Mitomycin C (MMC)
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Shaogang Wang
Bladder Cancer
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
The purposes of this study are to: find out whether participants' cancer returns or gets worse while they are taking lenalidomide and Bacille Calmette-Guerrin (BCG); evaluate the safety and tolerability of the combination of…
- Trial name
- NCT01373294
- Testing
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer.
- Trial name
- HERO (NCT07207824)
- Testing
- Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Bladder Cancer
Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients
The analysis of cell-free tumor DNA (cfDNA) in plasma has emerged as a clinically relevant predictive and prognostic biomarker in several metastatic solid malignancies, and even now represents standard-of-care for prescription of…
- Trial name
- ALU (NCT04412070)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hopital Foch
Bladder Cancer
Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer
RATIONALE: Studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably.
- Trial name
- NCT00553124
- Testing
- selenium, vitamin E, biopsy
- Where
- United Kingdom
- Volunteers
- 3,400 people
- Sponsor
- University Hospital Birmingham
Bladder (Urothelial, Transitional Cell) Cancer
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
The goal of this exploratory study is to evaluate the safety and efficacy of nimotuzumab combined with chemoradiotherapy in bladder - preserving treatment for MIBC patients who are ineligible for or decline radical cystectomy.
- Trial name
- NCT07053735
- Testing
- Nimotuzumab and Radiotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Bladder Cancer
Lateral Prostate Capsule Sparing Versus Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male
To compare the perioperative, functional, and oncologic outcomes between nerve sparing and lateral prostate capsule sparing robot-assisted radical cystectomy with orthotopic ileal neobladder in male patients with bladder cancer.
- Trial name
- NCT04966949
- Testing
- lateral prostate capsule sparing or neurovascular bundles sparing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.